Key Takeaways:
Jim Cramer declared biotech the market's hottest group, predicting a wave of M&A deals after years of regulatory gridlock.
Jim Cramer called biotech the hottest group in the market, predicting a flood of mergers and acquisitions as a friendlier regulatory environment under new FDA leadership unlocks dealmaking that stalled for years.
"There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA," Cramer said on CNBC's Mad Dash segment July 6. "If you look at that chart, this is the group that's the hottest group in the market."
Cramer argued that takeover activity slowed after an Amgen acquisition nearly faced regulatory opposition under the prior administration. "We have now waited for so many companies because there have been so few takeovers," he said, predicting "these deals are going to be flooding the market according to my sources."
The call comes as major biopharma companies are already executing the playbook. Eli Lilly reported Q1 revenue of $19.8 billion, up 55.5 percent year over year, and completed four acquisitions in the quarter — Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics and Ajax Therapeutics. Gilead Sciences closed its $7.8 billion Arcellx acquisition for the multiple myeloma therapy Anito-cel and signed two additional deals worth a combined $2.2 billion.
Cramer identified Vertex Pharmaceuticals and Regeneron Pharmaceuticals as the types of "confirmed-data franchises" that command premium acquisition prices. Regeneron's Dupixent, developed with Sanofi, generated $4.88 billion in global sales in the most recent quarter, underscoring the revenue scale that acquirers target. Lilly raised its full-year revenue guidance to a range of $82 billion to $85 billion, giving it ample firepower for further deals.
The shift in FDA leadership has been the critical variable. Under the prior administration, the near-blocking of an Amgen deal created a chilling effect that froze biotech M&A for years, according to Cramer's sources. The thaw has been immediate: Lilly alone snapped up four companies in a single quarter, spanning gene therapy, RNA therapeutics and oncology small molecules.
For investors, the question is which companies become acquirers and which become targets. Lilly trades at a premium multiple supported by its GLP-1 franchise — Mounjaro generated $8.66 billion in sales and Zepbound added $4.16 billion in the US — giving it currency for stock-based acquisitions. Gilead's $7.8 billion Arcellx bet signals confidence in cell therapy for multiple myeloma, a $7 billion addressable market that is expected to grow as frontline approvals expand. Vertex, with its cystic fibrosis monopoly and a pipeline in pain and type 1 diabetes, fits Cramer's description of a franchise that would command a premium in any takeover scenario.
This article is for informational purposes only and does not constitute investment advice.
